Wave Life Sciences Ltd.
WVENext catalyst
WVE-006
Alpha-1 Antitrypsin Deficiency
Get an email about WVE's next catalysts
Track Wave Life Sciences (WVE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 2 past
WVE-006 Phase 2 Est. Readout
Estimated primary completion for WVE-006 trial (NCT06405633) in Alpha-1 Antitrypsin Deficiency. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
WVE-006
Alpha-1 Antitrypsin Deficiency
WVE-N531
Duchenne Muscular Dystrophy
SAD: WVE-003
Huntington Disease
WVE-007
Overweight and Obesity
MD: WVE-003
Huntington Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
WVE-006 | Phase 2 | Alpha-1 Antitrypsin Deficiency | - | - |
WVE-N531 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
SAD: WVE-003 | Phase 2 | Huntington Disease | - | - |
WVE-007 | Phase 2 | Overweight and Obesity | - | - |
MD: WVE-003 | Phase 2 | Huntington Disease | - | - |
Frequently asked questions
What is in Wave Life Sciences Ltd.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Wave Life Sciences Ltd.'s (WVE) pipeline across Phase 2. Its lead program is WVE-006 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Wave Life Sciences Ltd.'s next FDA catalyst?→
Wave Life Sciences Ltd.'s (WVE) next tracked catalyst is a Phase 2 readout expected September 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track WVE biotech catalysts?→
Add WVE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Wave Life Sciences Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.